Our in vivo and in vitro results showed that MAD2L2 suppressed CRC development by down‐regulating NCOA3, and our clinical data suggested that MAD2L2 predicted favorable prognosis in CRC patients. This evidence concerns the gene MAD2L2 and colorectal carcinoma.